# US 2003/0229085 A1 · 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229085 A1
- Document ID: US20030229085A1
- Status: Published application
- Kind: A1
- Application number: 10/366,688
- Filed: 2003-02-14
- Published: 2003-12-11
- Earliest claimed: 2002-02-15
- Assignees: Schering Corporation
- Inventors: Thorsten Blume; Wolfgang Halfbrodt; Joachim Kuhnke; Ursula Moenning; Bernd Elger; Herbert Schneider
- Web page: https://patentgrep.com/patent/US20030229085A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

New benzimidazole derivatives are described, their production and their use for the production of pharmaceutical agents for treatment and prevention of diseases that are associated with a microglia activation and T-cell-mediated immunological diseases, as well as pharmaceutical preparations that contain the new benzimidazole derivatives.

## Claims

### Claim 1

Benzimidazole derivatives of general formula I
5
in which
R1 is a phenyl group that is optionally substituted with up to three of the following substituents, independently of one another:
F, Cl, Br, I
OH, OR4, OCOR4
SR4, SOR4, SO2R4,
R4,
NH2, NR4,NR4R4′
or two adjacent substituents at R1 together form an O—CH2—O—, —O—CH2—CH2—O— or —CH2—CH2—CH2— group,
R2 is a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms, selected from N, S and O, which optionally is substituted with up to two of the following substituents, independently of one another:
F, Cl, Br, I
OH, OR4, OCOR4,
COR4,
SR4, SOR4, SO2R4,
R4,
or two adjacent substituents at R2 together form an —O—CH2—O—, —O—CH2—CH2—O— or —CH2—CH2—CH2— group,
R3 is H, OH or O—C1-6-alkyl,
R4 and R4′, independently of one another, are C1-4-perfluoroalkyl or C1-6-alkyl,
A is a C2-6-alkylene group, which optionally is substituted with ═O, OH, O—C1-3-alkyl, NH2, NH—C1-3-alkyl, NH—C1-3-alkanoyl, N(C1-3-alkyl)2, and N(C1-3-alkyl)(C1-3-alkanoyl),
B is COOH, CONH2, CONHNH2, CONHR5, CONR5R5, in each case bonded to a carbon atom of group A,
R5 and R5′, independently of one another, are in each case a radical, selected from the group that comprises C1-6-alkyl, C2-6-alkenyl, C2-6-alkinyl, whereby a C atom can be exchanged for O, S, SO, SO2, NH, N—C1-3-alkyl or N—C1-3-alkanoyl, and also (C0-3-alkanediyl-C3-7-cycloalkyl), whereby in a five-membered cycloalkyl ring, a ring member can be ring N or ring 0, and in a six- or seven-membered cycloalkyl ring, one or two ring members in each case can be ring-N atoms and/or ring-O atoms, whereby the ring-N atoms optionally can be substituted with C1-3-alkyl or C1-3-alkanoyl, as well as also (C0-3-alkanediyl-phenyl) and (C0-3-alkanediyl-heteroaryl), whereby the heteroaryl group is five- or six-membered and contains one or two heteroatoms that are selected from the group that comprises N, S and O,
whereby all above-mentioned alkyl and cycloalkyl radicals optionally can be substituted with up to two radicals that are selected from the group that comprises CF3, C2F5, OH, O—C1-3-alkyl, NH2, NH—C1-3-alkyl, NH—C1-3-alkanoyl, N(C1-3-alkyl)2, N(C1-3-alkyl)(C1-3-alkanoyl), COOH, CONH2 and COO—C1-3-alkyl, and all above-mentioned phenyl and heteroaryl groups optionally can be substituted with up to two radicals that are selected from the group that comprises F, Cl, Br, CH3, C2H5, OH, OCH3, OC2H5, NO2, N(CH3)2, CF3, C2F5 and SO2NH2
or R5 and R5′ together with the N atom form a five- to seven-membered heterocyclic ring that can contain another N or O or S atom and that can be substituted with C1-4-alkyl, (C0-2-alkanediyl-C1-4-alkoxy), C1-4-alkoxycarbonyl, aminocarbonyl or phenyl
as well as their optical or geometric isomers or tautomeric forms or pharmaceutically applicable salts,
whereby the following compounds are ruled out:
6-[[1-Phenyl-2-(pyridin-4-yl)-H-benzimidazol-6-yl]oxy]hexanoic acid,
6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid.

### Claim 2 (depends on 1)

Benzimidazoles according to claim 1, characterized in that
R1 is a phenyl group that optionally is substituted with up to two of the following substituents, independently of one another:
F, Cl,
OH, OR4, OCOR4
SR4,
R4 or
two adjacent substituents at R1 form an —O—CH2—O— or —CH2—CH2—CH2-group.

### Claim 3 (depends on 1, 2)

Benzimidazoles according to claim 1 or 2, wherein
R2 is a monocyclic 5- to 6-membered heteroaryl group with 1-2 heteroatoms, selected from the group that comprises N, S and O, which optionally is independently substituted with up to two of the following substituents:
F, C1,
OR4, OCOR4
SR4, SOR4, SO2R4,
R4 or
two adjacent substituents at R2 form an —O—CH2—O— or —CH2—CH2—CH2-group.

### Claim 4 (depends on 1, 2, 3)

Benzimidazoles according to one of claims 1-3, wherein R3 is H.

### Claim 5 (depends on 1, 2, 3, 4)

Benzimidazoles according to one of claims 1-4, wherein
R4 and R4′, independently of one another, are C1-2 perfluoroalkyl, and C1-4 alkyl.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Benzimidazoles according to one of claims 1-5, wherein
R5 and R5′, independently of one another, are C1-6 alkyl, whereby a carbon atom can be exchanged for O, S, SO, or SO2,
C3-5 cycloalkyl-C0-3 alkylene, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, whereby the ring nitrogen optionally is substituted with C1-3 alkyl or C1-3 alkanoyl,
C0-2 alkylene-(5- to 6-membered heteroaryl with 1-2 heteroatoms from N, S and O),
whereby all above-mentioned alkyl and cycloalkyl radicals can be substituted with CF3, OH, NH2, NH C1-3 alkyl, NH C1-3 alkanoyl, N(C1-3alkyl)2, N(C1-3 alkyl)(C1-3 alkanoyl), COOH, CONH2 and all above-mentioned heteroaryl groups with one or two substituents from the group that consists of F, Cl, CH3, C2H5, OCH3, OC2H5, CF3, C2F5,
or R5 and R5′ together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C1-4-alkyl or C1-4-alkoxy-C0-2-alkyl.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

Benzimidazoles according to one of claims 1-6, wherein
A is straight-chain C3-6-alkylene.

### Claim 8 (depends on 1, 2, 3, 4, 5, 7)

Benzimidazoles according to one of claims 1-5, 7, wherein
B is COOH or CONH2
in each case bonded to a carbon atom of group A.

### Claim 9 (depends on 1)

6-[[1-(4-Methylphenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid
5-[[1-(4-methylphenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]pentanoic acid
4-[[1-(4-methylphenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]butyric acid
6-[[1-(4-methylphenyl)-2-(4-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid
6-[[1-(4-methylphenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid
5-[[1-(4-methylphenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]pentanoic acid
4-[[1-(4-methylphenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]butyric acid
5-[[1-phenyl-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]pentanoic acid
4-[[1-phenyl-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]butyric acid
6-[[1-phenyl-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid
6-[[1-(4-fluorophenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid
5-[[1-(4-fluorophenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]pentanoic acid
6-[[1 (4-fluorophenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid
5-[[1-(4-fluorophenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]pentanoic acid
5-[[1-phenyl-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]pentanoic acid
4-[[1-phenyl-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]butyric acid
6-[[1-phenyl-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid
N-(3-methoxypropyl)-6-[[1-(4-methylphenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanamide
6-[[1-(4-methylphenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]-1-morpholin-1-ylhexan-1-one
N-methyl-6-[[1-(4-methylphenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanamide
N,N-dimethyl-6-[[1-(4-methyphenyl)-2-(3-pyridinyl)-1H-benzimidazo 1-6-yl]oxy]hexanamide
6-[[1-(4-methylphenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanamide
N-cyclopropyl-6-[[1-(4-methylphenyl)-2-(3-thieny)-1H-benzimidazol-6-yl]oxy]hexanamide
N-methyl-6-[[1-(4-methylphenyl-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanamide
6-[[1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]-1-(thiazolidin-3-yl)-hexan-1-one
N-(2-methoxyethyl)-5-[[1-(4-methylphenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]pentanamide
N,N-dimethyl-5-[[1-(4-methyphenyl)-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]pentanamide
5-[[1-(4-methylphenyl)-2-(3-pyridinyl)-H-benzimidazol-6-yl]oxy]pentanamide
6-[[1-(4-methylphenyl)-2-(2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid according to claim 1.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

Use of a compound according to one of claims 1-9 for the production of a pharmaceutical agent for treating or preventing diseases that are associated with a microglia activation.

### Claim 11 (depends on 10)

Use according to claim 10 for treating or preventing inflammatory, allergic, infectious or autoimmune diseases.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

Pharmaceutical agents that are characterized in that they contain one or more compounds according to one of claims 1-9 and one or more vehicles and/or adjuvants.
